# AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

> **NCT06196697** · PHASE2 · RECRUITING · sponsor: **Harbin Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Cadonilimab
- **BIOLOGICAL:** Ivonescimab
- **DRUG:** XELOX
- **DRUG:** SOX

## Key facts

- **NCT ID:** NCT06196697
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196697, "AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06196697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*